Brief: Inhibikase Therapeutics Announces Dosing Of First Subjects In Its '501' Bioequivalence Study Of Ikt-001Pro
12/12/2022 21:22
Dec 12 (Reuters) - Inhibikase Therapeutics Inc IKT.O :
* INHIBIKASE THERAPEUTICS ANNOUNCES DOSING OF FIRST SUBJECTS
IN
ITS '501' BIOEQUIVALENCE STUDY OF IKT-001PRO
Source text for Eikon: ID:nPncfJB0Ka
Further company coverage: IKT.O
((Reuters.Briefs@thomsonreuters.com))
Recent news on Inhibikase Therapeutics
See all newsBrief: Inhibikase Therapeutics Prices Public Offering Of 46 Million Shares At $1.45 Per Share
Brief: Inhibikase Therapeutics Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Inhibikase Therapeutics Advancing IKT-001 To Global Phase 3 Study In Pulmonary Arterial Hypertension
Cardiopulmonary drugmaker Inhibikase Therapeutics' Q3 net loss widens
Inhibikase Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary